CN108379649A - A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof - Google Patents

A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof Download PDF

Info

Publication number
CN108379649A
CN108379649A CN201810231364.9A CN201810231364A CN108379649A CN 108379649 A CN108379649 A CN 108379649A CN 201810231364 A CN201810231364 A CN 201810231364A CN 108379649 A CN108379649 A CN 108379649A
Authority
CN
China
Prior art keywords
biological
oral liquid
hemostatic oral
polysaccharide
biological polyoses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810231364.9A
Other languages
Chinese (zh)
Inventor
张博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201810231364.9A priority Critical patent/CN108379649A/en
Publication of CN108379649A publication Critical patent/CN108379649A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0042—Materials resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a kind of biological polyoses Hemostatic Oral Liquid, and the component of the biological polyoses Hemostatic Oral Liquid includes at least one of biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate and sodium chloride.Compared with prior art, 1) product prepared by the present invention is transparent or semitransparent viscous solution, convenient for being sprayed to the surface of a wound or ulcer surface；2) intraoperative hemorrhage can be effectively reduced, the visual field in art is kept；3) good interception can be played to postoperative tissue adhesions；4) biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate can be used in combination, and have synergistic effect, and the bleeding of gastrointestinal tract is also can effectively prevent while for stopping blooding in body surface, art；5) it can be degraded and absorb by body, good biocompatibility reduces the generation of surgical risks factor；6) contain fungicide when, can effectively prevent in art, postoperative bacterium, virus infection.The product prepared using the present invention can clear up exudation and oozing of blood, clear surgical field of view, improve surgical quality, reduce postoperative complications.

Description

A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof
Technical field
The present invention relates to medical material tech fields, and in particular to a kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof.
Background technology
Wound or perioperative bleeding following, oozing of blood, usually induce systemic or locality, immediacy or Delayed Complications, Lead to adverse consequences or even threat to life.Surgical operation abnormal bleeding rate is 0.5%~40% according to statistics, and openheart surgery is reachable 12%.Topical application is developed, rapid hemostasis, the hemostasia products for protecting the surface of a wound can effectively reduce the hand caused by bleeding Error during art can also play the bleeding caused by all kinds of wounds, burn and scald the work for the wound healing that stops blooding at once, accelerates With in crucial moment redemption life.
And common some hemostasia products are mostly hemostatic gauze, styptic powder etc. on the market, these products table in practice Reveal inconvenient to use, poor biocompatibility, big to tissue stimulation, slow with bleeding, oozing of blood location contacts, extra hemostat is in office The shortcomings of portion assembles, after influencing more.
Invention content
To solve the above problems, the present invention provides a kind of degradable absorbable biological polyoses Hemostatic Oral Liquid, the biology is more The component of sugared Hemostatic Oral Liquid includes at least one of biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate and sodium chloride.
Preferably, the biological polyoses Hemostatic Oral Liquid further includes one or more in polyethylene glycol, fungicide.
Preferably, the biological polysaccharide derivative is carboxymethyl cellulose ether, cellulose carboxyethyl ester, cellulose ethyl Ether, ethyl cellulose or methoxycellulose.
Preferably, the viscosity of the biological polysaccharide derivative is 10~600cps, degree of substitution 0.6~1.2.
Preferably, it is calculated according to mass percent, in the biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate extremely A kind of few component of composition, accounts for the 0.2%~10% of Hemostatic Oral Liquid gross mass.
Preferably, the polyethylene glycol is medical polyethylene glycol of the average molecular weight 200~10000, more preferably, The polyethylene glycol is medical polyethylene glycol of the average molecular weight 200~6000.
Preferably, the fungicide is tobramycin, Ciprofloxacin Hydrochloride, erythromycin, azithromycin or macrolides Antibiotic.
Preferably, the biological polyoses Hemostatic Oral Liquid is transparent or semitransparent solution.
Biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate itself have the function of hemostasis and wound healing, can be with Layer of gel film is formed in wound surface by hydrophilic radical, while providing good healing environment to wound, plays one The effect of preventing adhesion of fixed physical barrier.
Another object of the present invention is to provide a kind of methods preparing above-mentioned biological polyoses Hemostatic Oral Liquid, including following step Suddenly：
1) biological polyoses are prepared：Using ɑ-cellulose as raw material, through the controllable physical and chemical reaction such as peroxidating, alkalization, etherificate, refine Water-soluble biological polysaccharide derivates are made；Callicarpa bodinieri Levl. is milled, Callicarpa bodinieri Levl. polysaccharide is extracted with ethanol solution；
2) dissolving is blended：By at least one of biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate, sodium chloride, poly- second Glycol and/or fungicide dissolve by heating in aqueous solution, are cooled to room temperature, and adjust pH to 4~8；
3) it deaerates, filter：Ultrasound or vacuum outgas, pressure filtration after being dissolved under cleaning condition；
4) filling：It is filling under aseptic condition；
5) it sterilizes：Co 60 ray sterilizing or high pressure steam sterilization.
Herein, " comprising " refers to that the other compositions for influencing final result can be added not.The term includes " by ... group At " and " substantially by ... form ".
It is compared with the prior art, the beneficial effects of the invention are as follows：1) product prepared by the present invention is transparent or semitransparent Viscous solution, convenient for being sprayed to the surface of a wound or ulcer surface；2) intraoperative hemorrhage can be effectively reduced, the visual field in art is kept；It 3) can be to art Tissue adhesions play good interception afterwards；4) biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate can be used in combination, tool There is synergistic effect, the bleeding of gastrointestinal tract is also can effectively prevent while for stopping blooding in body surface, art；5) it can be degraded and inhale by body It receives, good biocompatibility, reduces the generation of surgical risks factor；6) when containing fungicide, it can effectively prevent in art, is postoperative Bacterium, virus infection.The product prepared using the present invention can clear up exudation and oozing of blood, clear surgical field of view, improve operation matter Amount reduces postoperative complications.The flushing liquor that Hemostatic Oral Liquid prepared by the present invention can solve clinically to use at present is only used for hand The physical washing problems at art position.Lubrication isolation can be played to the tissue surface of a wound, mucous membrane, skin and biology shields while rinsing There is good hemostasis and auxiliary to prevent post-operation adhesion for the effect of barrier.
Specific implementation mode
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments to the present invention Specific implementation mode further illustrate.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, and It is not used in the restriction present invention.
Embodiment 1
Biological polysaccharide derivative -- the preparation of carboxymethyl cellulose ether
Medical absorbent cotton fiber is added in the hydrogen peroxide solution that configuration concentration is 2%, and cycle leaching is even, and hydroxide is added in drying Sodium solution is warming up to 30~85 DEG C, stirs evenly, and carries out taking out after dynamic chemical combines 0.5~12h under ultrasound condition, is added one Chloroacetic acid solution continues dynamic chemical and combines 1~30h, takes out, and adjusts pH, drying；Into 60~95% ethanol solution Addition disodium hydrogen phosphate, dibastic sodium phosphate, arasaponin, sorbitan fatty acid ester -80, carbomer, raising temperature to 10~ It 70 DEG C, stirs evenly, above-mentioned processed medical absorbent cotton fiber is added, dynamic chemical is carried out under conditions of stirring or ultrasonic vibration In conjunction with 2-12h dryings, drying.
Embodiment 2
Biological polysaccharide derivative -- the preparation of carboxymethyl cellulose ether
Medical absorbent cotton fiber is added in the hydrogen peroxide solution that configuration concentration is 3%, and cycle leaching is even, and hydroxide is added in drying Sodium solution is warming up to 20~65 DEG C, stirs evenly, and carries out taking out after dynamic chemical combines 0.5~10h under ultrasound condition, is added one Chloroacetic acid solution continues dynamic chemical and combines 3~30h, takes out, and adjusts pH, drying.In 50~95% ethanol solution, Panaxoside, sodium carboxymethylcellulose, Tween-80, phosphate buffer is added, increases temperature to 20~60 DEG C, stirs evenly, Above-mentioned processed medical absorbent cotton fiber is added, dynamic chemical combination 2-12h is carried out under conditions of stirring or ultrasonic vibration Drying, drying.
Embodiment 3
Weigh viscosity about 600, degree of substitution 0.8~0.9 carboxymethyl cellulose ether 1g, be added in 50ml physiological saline, Heating is stirred under confined conditions to being completely dissolved, and tobramycin 100mg is added, and ultrasound or vacuum outgas, press filtration are sterile in hundred grades Under the conditions of it is filling in spray bottle, Co 60 ray sterilizing to get.According to《GB/T 16886.9-2001 medical instrument biology is commented Valence》9th part：The qualitative and quantitative frame requirements of potential catabolite carry out zoopery, animal experiments show that 6 weeks in vivo Inside fully absorb.
Embodiment 4
Weigh viscosity about 500, degree of substitution 0.9~0.95 methoxycellulose 0.8g, Callicarpa bodinieri Levl. polysaccharide 0.2g, mean molecule Amount is 300 polyethylene glycol 2g, is added in 50ml physiological saline, is stirred under confined conditions de- to ultrasonic or vacuum is completely dissolved Gas, press filtration is filling, 121 DEG C of high pressure steam sterilizations to get.According to《GB/T16886.9-2001 BiologicalEvaluationofMedicalDevices》 9th part：The qualitative and quantitative frame requirements of potential catabolite carry out zoopery, animal experiments show that 2~4 weeks in vivo It fully absorbs.
Embodiment 5
Weigh viscosity about 200, degree of substitution 0.8~1.0 carboxymethyl cellulose ether 0.6g, Callicarpa bodinieri Levl. polysaccharide 0.5g, alginic acid Sodium 0.05g, is added in 50ml physiological saline, is stirred under confined conditions to being completely dissolved, ultrasound or vacuum outgas, press filtration fill Dress, sterilizing to get.According to《GB/T 16886.9-2001 BiologicalEvaluationofMedicalDevices》9th part：Potential catabolite Qualitative and quantitative frame requirements carry out zoopery, animal experiments show that fully absorbing within 2~4 weeks in vivo.
Embodiment 6
Weigh viscosity about 300, degree of substitution 0.8~0.85 cellulose carboxyethyl ester 0.7g, Callicarpa bodinieri Levl. polysaccharide 0.6g is added to In 50ml physiological saline, stirred under confined conditions to being completely dissolved, ultrasound or vacuum outgas, press filtration is filling, sterilizing to get.Root According to《GB/T 16886.9-2001 BiologicalEvaluationofMedicalDevices》9th part：The qualitative and quantitative frame of potential catabolite is wanted Carry out zoopery is asked, animal experiments show that fully absorbing within 2~4 weeks in vivo.
Embodiment 7
Weigh viscosity about 400, degree of substitution 0.9~1.0 ethyl cellulose 0.8g, sodium alginate 0.45g, average molecular weight It for 200 polyethylene glycol 4.5g, is added in 50ml physiological saline, is stirred under confined conditions to being completely dissolved, hydrochloric acid ring is added Third husky star 95mg, ultrasound or vacuum outgas, press filtration is filling, sterilizing to get.According to《GB/T 16886.9-2001 medical instruments Biological assessment》9th part：The qualitative and quantitative frame requirements of potential catabolite carry out zoopery, animal experiments show that It fully absorbs within 2~4 weeks in vivo.
Embodiment 8
Weigh viscosity about 100, degree of substitution 0.8~0.9 cellulose ethyl ether 0.6g, Callicarpa bodinieri Levl. polysaccharide 0.35g, sodium alginate 0.15g, the polyethylene glycol 2.5g that average molecular weight is 6000, is added in 50ml physiological saline, is stirred under confined conditions to complete Fully dissolved, ultrasound or vacuum outgas, press filtration is filling, sterilizing to get.According to《GB/T 16886.9-2001 medical instrument biologies Learn evaluation》9th part：The qualitative and quantitative frame requirements of potential catabolite carry out zoopery, animal experiments show that in body It fully absorbs within interior 2~4 weeks.
Comparative example 1
The Hemostatic Oral Liquid and control group medical hemostatic gauze prepared using above method carries out contrast experiment.In basis《GB/T 16886.6-1997 BiologicalEvaluationofMedicalDevice》After the implantation of 6th part in local reaction experiment, the rat bleeding of this product is used Amount and bleeding stopping period are obviously fewer than control group amount, the time is short.After the use of abdominal cavity position, normal diet and defecation time compare control group It is short.Operative site test sample group is without being adhered no inflammatory cell infiltration, good biocompatibility after 6 weeks, control group hyperplasia, glutinous in a organized way Even phenomenon.

Claims (9)

1. a kind of biological polyoses Hemostatic Oral Liquid, the component of the biological polyoses Hemostatic Oral Liquid include biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, At least one of sodium alginate and sodium chloride.
2. biological polyoses Hemostatic Oral Liquid as described in claim 1, which is characterized in that further include one in polyethylene glycol, fungicide Kind is a variety of.
3. biological polyoses Hemostatic Oral Liquid as claimed in claim 1 or 2, which is characterized in that the biological polysaccharide derivative is fiber Plain carboxymethyl ester, cellulose carboxyethyl ester, cellulose ethyl ether, ethyl cellulose or methoxycellulose.
4. biological polyoses Hemostatic Oral Liquid as claimed in claim 3, which is characterized in that the viscosity of the biological polysaccharide derivative is 10 ~600cps, degree of substitution 0.6~1.2.
5. biological polyoses Hemostatic Oral Liquid as claimed in claim 4, which is characterized in that calculated according to mass percent, the biology At least one of polysaccharide derivates, Callicarpa bodinieri Levl. polysaccharide, sodium alginate composition component, account for Hemostatic Oral Liquid gross mass 0.2%~ 10%.
6. biological polyoses Hemostatic Oral Liquid as claimed in claim 2, which is characterized in that the polyethylene glycol is that average molecular weight exists 200~10000 medical polyethylene glycol.
7. biological polyoses Hemostatic Oral Liquid as claimed in claim 2, which is characterized in that the fungicide is tobramycin, hydrochloric acid ring Third husky star, erythromycin, azithromycin or macrolide antibiotics.
8. biological polyoses Hemostatic Oral Liquid as described in claim 1, which is characterized in that the biological polyoses Hemostatic Oral Liquid is transparent or half Transparent solution.
9. a kind of method preparing any biological polyoses Hemostatic Oral Liquids of claim 1-8, includes the following steps：
1) biological polyoses are prepared：Using ɑ-cellulose as raw material, through the controllable physical and chemical reaction such as peroxidating, alkalization, etherificate, refined it is made Water-soluble biological polysaccharide derivates；Callicarpa bodinieri Levl. is milled, Callicarpa bodinieri Levl. polysaccharide is extracted with ethanol solution；
2) dissolving is blended：By at least one of biological polysaccharide derivative, Callicarpa bodinieri Levl. polysaccharide, sodium alginate, sodium chloride, polyethylene glycol And/or fungicide dissolves by heating in aqueous solution, is cooled to room temperature, and adjusts pH to 4~8；
3) it deaerates, filter：Ultrasound or vacuum outgas, pressure filtration after being dissolved under cleaning condition；
4) filling：It is filling under aseptic condition；
5) it sterilizes：Co 60 ray sterilizing or high pressure steam sterilization.
CN201810231364.9A 2018-03-20 2018-03-20 A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof Pending CN108379649A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810231364.9A CN108379649A (en) 2018-03-20 2018-03-20 A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810231364.9A CN108379649A (en) 2018-03-20 2018-03-20 A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof

Publications (1)

Publication Number Publication Date
CN108379649A true CN108379649A (en) 2018-08-10

Family

ID=63067797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810231364.9A Pending CN108379649A (en) 2018-03-20 2018-03-20 A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof

Country Status (1)

Country Link
CN (1) CN108379649A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551233A (en) * 2019-09-29 2019-12-10 中国药科大学 Callicarpa kwangtungensis polysaccharide and extraction method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1505530A (en) * 2001-04-30 2004-06-16 ������֯��ѧ�о��� Water soluble cellulose etherified derivates styptic materials
US20080131477A1 (en) * 2001-04-11 2008-06-05 Chin-Feng Yi Device and method for tissue engineering
CN102886066A (en) * 2012-10-19 2013-01-23 青岛大学 Preparation method of calcium-containing soluble hemostatic material
CN103263434A (en) * 2013-06-03 2013-08-28 张岩 Anti-adhesion liquor for wound washing and surgery and preparation method and application of anti-adhesion liquor
CN103977449A (en) * 2014-06-04 2014-08-13 张巍 Blended liquid hemostatic composite material and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131477A1 (en) * 2001-04-11 2008-06-05 Chin-Feng Yi Device and method for tissue engineering
CN1505530A (en) * 2001-04-30 2004-06-16 ������֯��ѧ�о��� Water soluble cellulose etherified derivates styptic materials
CN102886066A (en) * 2012-10-19 2013-01-23 青岛大学 Preparation method of calcium-containing soluble hemostatic material
CN103263434A (en) * 2013-06-03 2013-08-28 张岩 Anti-adhesion liquor for wound washing and surgery and preparation method and application of anti-adhesion liquor
CN103977449A (en) * 2014-06-04 2014-08-13 张巍 Blended liquid hemostatic composite material and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱胤龙: "《实用临床中药学》", 31 July 2013 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551233A (en) * 2019-09-29 2019-12-10 中国药科大学 Callicarpa kwangtungensis polysaccharide and extraction method and application thereof
CN110551233B (en) * 2019-09-29 2021-06-25 中国药科大学 Callicarpa kwangtungensis polysaccharide and extraction method and application thereof

Similar Documents

Publication Publication Date Title
US9220676B2 (en) Injectable in-situ crosslinked hydrogel and methods of making and using thereof
CN101001649B (en) Haemostatic composition comprising hyaluronic acid and its preparation method
CN102216381B (en) Can the polyoses grain of rehydration and spongy body
CA2817405C (en) Medical absorbable hemostatic material for bone wounds and preparation method therefor
US20180110897A1 (en) Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field
JP6962919B2 (en) Dissolvable nasal sponge
CN103263434B (en) Anti-adhesion liquor for wound washing and surgery and preparation method and application of anti-adhesion liquor
US10434212B2 (en) Degradable haemostat composition
JP2014138890A (en) Biocompatible modifed starch material capable of hemostasis, adhesion prevention, fusion promotion and surgical sealing
JP6491647B2 (en) Chitosan paste wound dressing
US20080152698A1 (en) Hydrogel
US20170258958A1 (en) Degradable haemostat composition
CN107158452B (en) Bone wound hemostatic composition and preparation method and application thereof
JP2009514597A (en) Bioabsorbable hemostatic gauze
JP3796165B2 (en) Anti-adhesive material
CN107823699A (en) Bleeding stopping and adherence preventing film and preparation method thereof
CN108379649A (en) A kind of biological polyoses Hemostatic Oral Liquid and preparation method thereof
WO2020162764A1 (en) Surgical hydrogel
CN105126158B (en) Polysaccharide fiber element hemostasis isolation antibacterial repairs glue and preparation method thereof
JP2022509912A (en) Compositions Containing Oxidized Cellulose
EP4329831A1 (en) Antimicrobial compositions
JP2010035744A (en) Adheshion preventive material
CN113908329B (en) Implantable hydrogel dressing and preparation method thereof
CN109847111B (en) Anti-adhesion material containing bletilla striata polysaccharide and preparation method thereof
CN111939313A (en) Cross-linked sodium hyaluronate hemostatic membrane material and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination